Pulmonary sarcoidosis
Not recruitingStudy on Efzofitimod for Treating Pulmonary Sarcoidosis in Patients
- Disease:Pulmonary sarcoidosis
- Substances:Efzofitimod
France- Participants:18–64 years · 65+ years
- Substances:Efzofitimod
- Sponsor:aTYR Pharma Inc.
Rare diseases
Investigational molecules
Locations
10240 Sorrento Valley Road Suite 300, 92121-1605, United States
aTyr Pharma Inc. is focused on clinical research in pulmonary sarcoidosis, a chronic inflammatory lung disease marked by immune-driven involvement of the respiratory system.
The sponsor’s research activity in this area centers on treatment options for patients with lung involvement and related respiratory impairment.
aTYR Pharma Inc. runs clinical trials in conditions such as Pulmonary sarcoidosis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.